TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2. (June 2015)

• Record Type: Journal Article
• Authors: Park, Su Bien; Lee, Ji Hae; Jeong, Won Wook; Kim, Yo Hwan; Cha, Hee Jeong; Joe, Yeonsoo; Chung, Hun Taeg; Cho, Wha Ja; Do, Jeong Wan; Lee, Byung Ju; Park, Jeong Woo; Ko, Byung Kyun
• Is Part Of: Journal of chemotherapy. Volume 27:Number 3(2015:Jun.)
• Page Start: 174
• Page End: 180
• Publication Date: 2015-06
• Subjects: TTP, -- Bcl-2, -- Cisplatin sensitivity, -- Head and neck squamous cell carcinoma; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1179/1973947814Y.0000000234
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : The chemotherapeutic agent cisplatin is widely used for treatment of head and neck squamous cell carcinoma (HNSCC). B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein that is overexpressed in cancer cells and confers resistance to cisplatin. Thus, inhibition of Bcl-2 expression may enhance the cisplatin sensitivity of cancer cells. In this study, we report that the AU-rich element (ARE) binding protein tristetraprolin (TTP) inhibits the expression of Bcl-2 and enhances cisplatin sensitivity of HNSCC cells. Cisplatin-sensitive HNSCC cells express high levels of TTP and low levels of Bcl-2, while cisplatin-resistant HNSCC cells have low levels of TTP and high levels of Bcl-2 . Inhibition of TTP expression using siRNA increases levels of Bcl-2 and decreases cisplatin sensitivity in HNSCC cells. On the contrary, overexpression of TTP decreases Bcl-2 expression and increases sensitivity to cisplatin. Together, the results of the present study suggest that TTP expression enhances cisplatin sensitivity in HNSCC cells by reducing levels of Bcl-2 .